Fail Faster: How Biopharma Companies Can Capitalize on Early Drug Development Failures

It typically takes 10 to 15 years to develop a new drug therapy, conduct clinical trials, and pass regulatory requirements. What’s more, only 9.6% of the drugs that enter clinical trials are approved by the Food and Drug Administration. In short, drug developers are facing an uphill battle as they seek to accelerate product development and improve clinical outcomes.

 

The methodology of “fail fast” focuses on spotting potential dead-ends early in the drug development cycle to reduce R&D costs, improve clinical outcomes, and speed time to market. The fail fast methodology is particularly important for small and medium-sized enterprises (SMEs) in the biopharmaceutical market who must be extremely resourceful on sometimes limited budgets. Therefore, 'failing faster' and recognizing potential pitfalls early on - ahead of costly clinical trials - becomes ever more critical.

 

Join us for a complimentary webinar where you'll hear from a panel of experts in biopharma discovery, R&D, and clinical trial design as they discuss the benefits and challenges of a fail fast strategy. Representatives from companies that have successfully adopted this innovative approach will participate as well, offering valuable insights on what worked—and what did not.

You'll learn:

 

  • When to implement 'fail fast' for maximum cost savings
  • How to use 'fail fast' tactics to validate drug targets
  • Where to shift your R&D strategies for optimal success

Featured Speaker

Shawn Iadonato, PhD
Chief Executive Officer
Kineta

Dr. Shawn Iadonato serves as Kineta’s Chief Executive Officer. He has over twenty years of experience leading startup biotech companies. Dr. Iadonato is a co-founder of Kineta and initially served as Chief Scientific Officer. Under his leadership at Kineta, the company established the proprietary PiiONEER™ screening platform for identifying innate immune fully human antibodies and has advanced novel drug programs in immuno-oncology, neuroscience and biodefense. The company also established strategic partnerships with Pfizer, Genentech and the Wellcome Trust.


Prior to founding Kineta, Dr. Iadonato co-founded and served as CSO of Illumigen Biosciences, Inc. At Illumigen Biosciences, he pioneered a patented drug discovery platform that relied upon recruitment and screening of healthy populations to elucidate their shared “wellness” genes. Dr. Iadonato also led the successful discovery and preclinical development of Illumigen’s antihepatitis C drug, which ultimately led to the sale of the company to Cubist Pharmaceuticals (now part of Merck & Co.) in 2007. Before Illumigen, Dr. Iadonato managed the Human Genome Center at the University of Washington. He is co-inventor on 49 issued U.S. and foreign patents. He is Principal Investigator or co-Investigator on numerous government grants and contracts. Dr. Iadonato received a PhD in Genetics from the University of Washington and is a graduate of the University of Pennsylvania.

Andrew A. Radin
Co-founder and Chief Executive Officer
Aria Pharmaceuticals

Andrew A. Radin is the co-founder and Chief Executive Officer of Aria Pharmaceuticals. Andrew created the company’s first drug development algorithms as part of his studies in biomedical informatics at Stanford University in 2014. Since co-founding Aria, Andrew was named an Emerging Pharma Leader by Pharma Executive magazine, was invited to give a TEDMED talk, and was named a Top 100 AI Leader by Deep Knowledge Analytics. In addition to his duties as CEO at Aria, Andrew serves as an advisor to Stanford University’s SPARK drug development and Stanford University’s StartX startup accelerator programs. Prior to co-founding Aria, Andrew served as Chief Technology Officer at several successful internet startups. His prior projects have reached tens of millions of people in telephony systems, advertising networks, video games, and geographical mapping systems. Andrew studied Biomedical Informatics at Stanford University’s SCPD graduate program and holds a Master of Science and Bachelor of Science degrees in Computer Science from Rochester Institute of Technology.

Nader Sanai, MD
J.N. Harber Professor of Neurological Surgery
The Barrow Neurological Institute

Nader Sanai, MD is the J.N. Harber Professor of Neurological Surgery at the Barrow Neurological Institute. His specialty neurosurgical practice is devoted to patients with benign and malignant brain tumors, particularly those in high-risk areas. He is a renowned expert in brain mapping techniques to identify and preserve areas of motor, sensory, and language function during surgery. As one of the nation’s highest-volume neurosurgical oncologists, Dr. Sanai was elected to the American Academy of Neurological Surgeons in 2016. In 2018, he founded and now directs the Ivy Brain Tumor Center, a not-for-profit drug development program specializing in Phase 0 trials and other pharmacokinetic- and pharmacodynamic-driven studies for brain tumors. Dr. Sanai has authored more than 200 peer-reviewed publications and delivered over 100 national and international lectures in neuro-oncology.

Date: Tuesday, June 7, 2022
Time: 2pm ET / 11am PT
Duration: 1 Hour

Register now for this webinar

© 2022 Questex LLC, All right reserved.

685 Third Avenue, 21st Floor New York, NY 10017

Reproduction in whole or part is prohibited.